JP2022532404A5 - - Google Patents

Info

Publication number
JP2022532404A5
JP2022532404A5 JP2021568319A JP2021568319A JP2022532404A5 JP 2022532404 A5 JP2022532404 A5 JP 2022532404A5 JP 2021568319 A JP2021568319 A JP 2021568319A JP 2021568319 A JP2021568319 A JP 2021568319A JP 2022532404 A5 JP2022532404 A5 JP 2022532404A5
Authority
JP
Japan
Prior art keywords
crystalline form
ray powder
powder diffraction
measured
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021568319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532404A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/054628 external-priority patent/WO2020230099A1/en
Publication of JP2022532404A publication Critical patent/JP2022532404A/ja
Publication of JP2022532404A5 publication Critical patent/JP2022532404A5/ja
Priority to JP2024045596A priority Critical patent/JP2024095697A/ja
Priority to JP2026005366A priority patent/JP2026086446A/ja
Withdrawn legal-status Critical Current

Links

JP2021568319A 2019-05-16 2020-05-15 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態 Withdrawn JP2022532404A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024045596A JP2024095697A (ja) 2019-05-16 2024-03-21 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態
JP2026005366A JP2026086446A (ja) 2019-05-16 2026-01-15 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962848857P 2019-05-16 2019-05-16
US62/848,857 2019-05-16
US201962949599P 2019-12-18 2019-12-18
US62/949,599 2019-12-18
PCT/IB2020/054628 WO2020230099A1 (en) 2019-05-16 2020-05-15 Crystalline forms of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024045596A Division JP2024095697A (ja) 2019-05-16 2024-03-21 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態

Publications (2)

Publication Number Publication Date
JP2022532404A JP2022532404A (ja) 2022-07-14
JP2022532404A5 true JP2022532404A5 (cg-RX-API-DMAC7.html) 2022-08-25

Family

ID=70775449

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021568319A Withdrawn JP2022532404A (ja) 2019-05-16 2020-05-15 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態
JP2024045596A Pending JP2024095697A (ja) 2019-05-16 2024-03-21 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態
JP2026005366A Pending JP2026086446A (ja) 2019-05-16 2026-01-15 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024045596A Pending JP2024095697A (ja) 2019-05-16 2024-03-21 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態
JP2026005366A Pending JP2026086446A (ja) 2019-05-16 2026-01-15 N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態

Country Status (22)

Country Link
US (3) US11407735B2 (cg-RX-API-DMAC7.html)
EP (2) EP4775572A2 (cg-RX-API-DMAC7.html)
JP (3) JP2022532404A (cg-RX-API-DMAC7.html)
KR (2) KR102945602B1 (cg-RX-API-DMAC7.html)
CN (1) CN114144232A (cg-RX-API-DMAC7.html)
AU (1) AU2020276701B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139812A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003011A1 (cg-RX-API-DMAC7.html)
DK (1) DK3969117T3 (cg-RX-API-DMAC7.html)
ES (1) ES3070743T3 (cg-RX-API-DMAC7.html)
FI (1) FI3969117T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260615T1 (cg-RX-API-DMAC7.html)
IL (1) IL287995A (cg-RX-API-DMAC7.html)
LT (1) LT3969117T (cg-RX-API-DMAC7.html)
MX (1) MX2021013970A (cg-RX-API-DMAC7.html)
PL (1) PL3969117T3 (cg-RX-API-DMAC7.html)
PT (1) PT3969117T (cg-RX-API-DMAC7.html)
RS (1) RS68078B1 (cg-RX-API-DMAC7.html)
SI (1) SI3969117T1 (cg-RX-API-DMAC7.html)
TW (2) TW202444706A (cg-RX-API-DMAC7.html)
WO (1) WO2020230099A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444706A (zh) 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
EP4353230A3 (en) 2020-01-28 2024-06-19 Teva Pharmaceuticals International GmbH Solid state forms of asciminib and process for preparation thereof
AU2021377336A1 (en) * 2020-11-16 2023-07-06 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
WO2022206937A1 (zh) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法
CN114369085B (zh) * 2021-12-27 2023-01-03 武汉九州钰民医药科技有限公司 盐酸Asciminib的制备方法
EP4615831A1 (en) * 2022-11-10 2025-09-17 Synthon B.V. Crystalline form of asciminib hydrochloride
WO2024257116A1 (en) * 2023-06-13 2024-12-19 Natco Pharma Limited Novel polymorphic forms of asciminib and its pharmaceutical salts thereof
EP4758138A1 (en) * 2023-08-07 2026-06-17 Biophore India Pharmaceuticals Pvt. Ltd. A process for the preparation of solid forms of n-[4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
KR20150008406A (ko) 2012-05-15 2015-01-22 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
ES2670601T3 (es) * 2012-05-15 2018-05-31 Novartis Ag Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
MX2015008427A (es) 2012-12-27 2015-10-22 Zentiva Saglik Ürünleri San Ve Tic A S Proceso de granulacion en seco para producir composiciones de comprimidos de metformina y sus composiciones.
SG10201900648SA (en) 2014-07-25 2019-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
EP3292870A1 (en) 2016-09-08 2018-03-14 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Fibronectin for use in the treatment of leukemia
US20200017482A1 (en) 2016-09-27 2020-01-16 Novartis Ag Surfactant systems for crystallization of organic compounds
WO2019084499A1 (en) 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TW202444706A (zh) 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Similar Documents

Publication Publication Date Title
TWI670270B (zh) 包含jak抑制劑之醫藥組合物
KR101151117B1 (ko) 경구 투여가능한 고체 제약 조성물의 제조 방법
JP7456721B2 (ja) 5-メチル-1-フェニル-2-(1h)-ピリドンの顆粒製剤及びその製造方法
KR101257919B1 (ko) 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 경구용 고형 제제 및 이의 제조방법
CA2700844A1 (en) Stable imatinib compositions
PL211062B1 (pl) Kompozycja farmaceutyczna do podawania doustnegozawierająca flibanserynę oraz zastosowanie kompozycji
TW201211025A (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists
JP2020200348A (ja) 光安定性を向上したシロドシン含有着色錠剤
JP7407364B2 (ja) ラメルテオン含有固形製剤
JP7378279B2 (ja) ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7628020B2 (ja) アキシチニブを有効成分とする医薬錠剤
TH2101007067A (th) รูปผลึกของ n-[4-(คลอโรไดฟลูออโรเมทอกซี)ฟีนิล]-6-[(3r)-3-ไฮดรอกซีไพรโรลิดิน-1-อิล]-5-(1h-ไพราโซล-5-อิล)ไพริดีน-3-คาร์บอกซาไมด์
KR101578627B1 (ko) 실로도신의 용출 특성이 향상된 약제학적 제제
JP2020152707A (ja) 安定化されたエソメプラゾールマグネシウム水和物含有腸溶性固形製剤
RU2024129605A (ru) Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида
KR101524264B1 (ko) 발사르탄 함유 경구용 약학 조성물
JP2015504913A (ja) 安定な非晶質のラルテグラビルカリウムプレミックス、及び、その調製方法
JP2021024820A (ja) 光安定性が向上した、ダサチニブ無水物フィルムコーティング錠剤
RU2021136800A (ru) Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида
JP4684545B2 (ja) 溶出性の良好なイソキサゾール誘導体経口製剤
JP6199922B2 (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
JP3968687B2 (ja) 易吸収性ニルバジピン錠
JP5065519B1 (ja) 結晶性アトルバスタチンカルシウム含有錠剤の製造方法
JP5563371B2 (ja) クエチアピンフマル酸塩含有経口用錠剤
JP7579091B2 (ja) アキシチニブを有効成分とする医薬錠剤及びその製造方法